Research & Development
Eisai Product Creation Systems (EPCS)
The Eisai Group has defined its R&D activities as product creation and established a new organization, Eisai Product Creation Systems (EPCS), to promote product creation.
Under the new EPCS, the Eisai Group aspires to become more patient-oriented in product creation.
The goal of EPCS is to better understand the emotions and realities of patients in order to provide innovative treatments that address their apparent and latent issues, thereby improving their quality of life.
EPCS combines venture-like productivity and speed with the knowledge resources of a global pharmaceutical company. Under this system, the Eisai Group aims to shorten development time so as to ensure the early creation of novel, innovative drugs that satisfy unmet medical needs or that improve the quality of life of patients and their caregivers.
Structure and Function of EPCS
EPCS encompasses Product Creation Units (PCUs), Core Function Units (CFUs), and the CEO office.
The PCUs, which comprise six units, including oncology and neurology, take full responsibility for conducting the series of processes ranging from the discovery of innovative drug candidates through NDA filing and obtaining approval. The CFUs, which comprise six units, including CMC and DMPK/TOX, take full responsibility for obtaining or maintaining world-class functional capabilities in the core functions of preclinical and clinical operations, technology, and regulatory affairs as well as promoting new drug development as an equal partner to the PCUs. A total of 12 units cooperate to create new products using an interactive approach. The CEO office is responsible for the formulation of product creation structural strategy, corporate portfolio management, and the promotion of product creation activities.
With this new system, the Eisai Group is building an organization made up of autonomous units with clear responsibilities and which are specialized in each disease or technology area so as to encourage a sense of ownership and motivate employees to increase their productivity and efficiency.
Overview of Eisai Product Creation Systems (EPCS)
PCU: Product Creation Unit
CFU: Core Function Unit
The Advantage of EPCS and Initiatives to Shorten Development Times
The Eisai Group has comprehensive product creation expertise that is capable of developing both small molecular compounds and biologics, and pursues drug innovation activities using both approaches. Specifically, the Group has unique platforms in the fields of Alzheimer's disease, sepsis, and immune and inflammatory response, and this ability to undertake continuous drug discovery activities contributes to the superiority of EPCS.
Under EPCS, the fully authorized units will reduce development times through appropriate decision making based on the discovery of truly innovative substances, which encompasses superior biomarker imaging research, rapid clinical studies with efficiencies of scale, safety and disposition studies extrapolated from clinical practice, the timely supply of high-quality trial drugs and pharmaceutical ingredients for research purposes, and a superior regulatory strategy.
Major R&D Pipeline List
Related Links
*For the latest information on R&D activities, please refer to the R&D section of the quarterly financial results and the accompanying reference materials.
